Trazodone Missed-Dose Protocol: What to Do and Why It Matters

The Exact Missed-Dose Decision Rule for Trazodone

The decision about a missed trazodone dose comes down to two variables: how much time has passed since your scheduled dose, and how much time remains before you need to function safely.

Trazodone's half-life of 5 to 9 hours means a single skipped bedtime dose will not erase your therapeutic antidepressant progress. The FDA prescribing information states patients should take a missed dose as soon as possible, but if it is almost time for the next dose, skip the missed one and continue on schedule. Doubling doses is explicitly contraindicated. [1]

When to Take the Missed Dose

Take the missed dose immediately if all three conditions apply:

• You are still in the same dosing day (or the same night, for bedtime use).
• You have at least 6 to 8 hours before you must drive, operate equipment, or perform safety-critical tasks.
• You have not already taken any other CNS depressants or alcohol since the missed dose window opened.

For most patients prescribed trazodone 50 to 100 mg at bedtime for sleep, this window is effectively closed by midnight if the intended dose was at 10 p.m. Taking a sedating agent at 2 a.m. And then waking at 6 a.m. Creates residual impairment, which is a documented safety hazard associated with next-morning drowsiness and falls in older adults. [2]

When to Skip the Dose Entirely

Skip the missed dose if any of the following apply:

• It is within 6 hours of your next scheduled dose.
• You will need to be alert within 8 hours (driving, childcare, machinery).
• You are on a once-daily bedtime regimen and it is already morning.

One missed bedtime dose of trazodone for insomnia has no meaningful pharmacodynamic consequence the following night. Sleep architecture does not destabilize from a single gap at sub-antidepressant doses. The situation differs somewhat for patients on 300 to 400 mg/day for major depressive disorder (MDD); even there, one missed day will not trigger withdrawal, though consistent adherence matters for maintaining steady-state plasma concentrations. [3]

The Double-Dose Prohibition

Never take two doses at once. Trazodone at supratherapeutic concentrations produces orthostatic hypotension (seen in up to 19.5% of patients in controlled studies) [1], excessive sedation, prolonged QTc interval, and, in rare cases, priapism. The risk-to-benefit ratio of a catch-up double dose is entirely unfavorable.

How Trazodone Works: Mechanism of Action

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). That label captures two distinct pharmacological actions that operate simultaneously and produce different clinical effects at different doses.

Serotonin Reuptake Inhibition

At higher doses (150 mg and above), trazodone inhibits the serotonin transporter (SERT), reducing presynaptic serotonin reuptake. This mechanism is shared with SSRIs such as sertraline and escitalopram. The reuptake inhibition component is what drives trazodone's antidepressant activity in MDD. [4]

Antidepressant response follows the same 2 to 6-week onset timeline seen with SSRIs. The American Psychiatric Association's 2010 practice guidelines for MDD list trazodone as a second-line option when sedation is a desired side effect or when initial agents have failed. [5]

Serotonin Receptor Antagonism

Trazodone is a potent antagonist at 5-HT2A and 5-HT2C receptors. At low doses (25 to 100 mg), the receptor antagonism dominates over reuptake inhibition because receptor binding occurs at lower plasma concentrations. This is why low-dose trazodone produces sedation without meaningful antidepressant effect, the serotonin reuptake inhibition threshold is not reached. [4]

The 5-HT2A antagonism also increases slow-wave (N3) sleep and reduces rapid eye movement (REM) sleep density. This profile explains the drug's widespread off-label use as a sleep aid, a use that predates most modern Z-drug and orexin-antagonist alternatives.

Alpha-1 Adrenergic and Histamine Antagonism

Trazodone also blocks alpha-1 adrenergic receptors, which accounts for orthostatic hypotension, dizziness, and the sedation that appears with the first dose. H1 histamine antagonism contributes modestly to sedation as well, though trazodone is far less antihistaminergic than older tricyclics such as amitriptyline. [4]

Understanding this receptor profile matters for missed-dose management: the sedative effect from a taken dose can persist 8 to 12 hours in some patients (particularly older adults with slower clearance), meaning a late compensatory dose risks additive next-day impairment.

Pharmacokinetics: Half-Life, Metabolism, and What They Mean Clinically

Absorption and Peak Concentration

Oral trazodone reaches peak plasma concentration (Tmax) in roughly 1 hour on an empty stomach. Food delays absorption and extends Tmax to about 2 hours, but increases bioavailability slightly and can reduce peak-related dizziness. Most clinicians advise taking it shortly after a light snack for this reason. [1]

Half-Life and Steady State

The elimination half-life is biphasic. The first phase runs 3 to 6 hours; the terminal phase extends to 5 to 9 hours in most adults, and up to 11 to 12 hours in individuals with hepatic impairment or in adults over 65. [1]

Steady-state plasma levels are reached within approximately 3 to 7 days of consistent dosing. A single missed dose in a patient at steady state causes a moderate but not clinically catastrophic drop in plasma trazodone concentration. The antidepressant effect is not an on/off switch; it depends on sustained receptor adaptation built over weeks.

Hepatic Metabolism and Drug Interactions

Trazodone is metabolized primarily by CYP3A4. Co-administration with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) increases plasma trazodone concentrations and amplifies the risk of adverse effects, including QTc prolongation. Strong CYP3A4 inducers (rifampin, carbamazepine) reduce exposure and may blunt efficacy. [1]

This metabolic pathway has a direct bearing on missed-dose decisions: a patient on a CYP3A4 inhibitor has slower clearance and longer effective drug duration, so that patient has more flexibility in the catch-up window before residual sedation becomes a hazard.

Renal Considerations

Less than 1% of trazodone is excreted unchanged in urine. Renal impairment does not materially affect dosing in most cases, though it may slow elimination of active metabolites. [1]

Trazodone for Sleep: What the Evidence Actually Shows

Trazodone is the most frequently prescribed medication for insomnia in the United States that is not a scheduled substance, yet its evidence base is narrower than most prescribers and patients realize.

Mendelson 2005 and the Evidence Gap

Mendelson's 2005 review in the Journal of Clinical Psychiatry evaluated the existing controlled trials of trazodone for primary insomnia and reached a sobering conclusion: available randomized controlled trial data were limited in duration, size, and quality. Most trials ran no longer than 2 weeks. The review noted that trazodone improved subjective sleep quality and reduced nighttime awakenings, but long-term efficacy and safety data were sparse. [6]

This does not mean trazodone is ineffective for sleep. It means the evidence standard is lower than what exists for, say, semaglutide or lemborexant. Clinicians prescribe it because it works in practice, lacks abuse potential, and is inexpensive.

Objective Sleep Architecture Effects

Polysomnographic studies show trazodone at 50 to 100 mg increases total sleep time, reduces sleep latency, and increases slow-wave sleep percentage. A small crossover study (N=15) comparing trazodone 50 mg to placebo found a statistically significant reduction in wake-after-sleep-onset (WASO) at night 1 (P<0.05), though the effect attenuated by week 6. [3]

For insomnia patients, this attenuation suggests trazodone may be most useful short-term or as a bridge while behavioral therapies (CBT-I) are initiated. The American Academy of Sleep Medicine's 2017 clinical practice guidelines gave trazodone a weak recommendation for sleep-onset and sleep-maintenance insomnia, citing the limited evidence quality. [7]

Trazodone vs. Z-Drugs for Sleep

Zolpidem and eszopiclone carry Schedule IV status, abuse potential, and FDA black-box warnings about complex sleep behaviors. Trazodone has none of those. The trade-off is next-day sedation (more common with trazodone), orthostatic hypotension (particularly in older adults), and the rare but serious risk of priapism.

For patients over 65, the American Geriatrics Society Beers Criteria (2023 update) lists trazodone as potentially inappropriate due to increased risk of orthostatic hypotension and fractures. [8] That is a meaningful clinical constraint when counseling elderly patients who miss a dose and ask whether to take it the next morning.

Trazodone for Depression: Dosing, Titration, and Adherence

Standard Antidepressant Dosing

The FDA-approved indication for trazodone is MDD. The labeled starting dose is 150 mg/day in divided doses, with titration in increments of 50 mg every 3 to 4 days as tolerated. The maximum recommended outpatient dose is 400 mg/day; hospitalized patients may receive up to 600 mg/day under close monitoring. [1]

Because the antidepressant dose range starts at 150 mg and extends well above the sleep dose range, patients prescribed trazodone for depression are taking significantly larger quantities. Missed doses at this tier carry more adherence weight.

Adherence and Steady-State Maintenance

Trazodone's antidepressant effect depends on sustained serotonergic adaptation, not single-dose pharmacology. A 2018 systematic review of antidepressant adherence found that partial adherence (defined as taking 80% or fewer prescribed doses) was associated with a 40% lower remission rate compared to full adherence across multiple antidepressants, though no trazodone-specific remission data were reported. [9]

The clinical implication is straightforward: one missed dose will not undo weeks of treatment, but a pattern of irregular dosing will.

Tapering When Stopping

Abrupt discontinuation of trazodone above 150 mg/day after more than 6 weeks of use can produce discontinuation symptoms including anxiety, irritability, and sleep disruption. These are less severe than SNRI discontinuation syndrome but still uncomfortable. The standard approach is to taper by 50 mg every 1 to 2 weeks. [1]

Patients who have missed several consecutive doses without intending to stop should contact their prescriber before resuming at the full dose, particularly if they have been on 300 mg or more.

Special Populations and Missed-Dose Adjustments

Older Adults (65+)

Hepatic clearance slows with age, extending trazodone's effective half-life. A missed bedtime dose in a 72-year-old on trazodone 75 mg should simply be skipped. Attempting to take the dose at 3 a.m. Risks morning orthostatic hypotension and fall risk. The Beers Criteria caution is directly applicable here. [8]

Hepatic Impairment

Patients with cirrhosis or significant hepatic impairment have reduced CYP3A4 capacity. Their trazodone concentrations run higher and persist longer. A missed dose in this population is less clinically significant from an efficacy standpoint and the same catch-up cautions apply: take it only if there is adequate time before alertness is required.

Pregnancy and Lactation

Trazodone is FDA Pregnancy Category C (historical designation) based on animal data showing fetal harm at high doses. If a pregnant patient misses a dose, she should follow the same same-day catch-up rule and consult her obstetrician before any dose adjustment. Trazodone is present in breast milk at low levels; the LactMed database classifies it as generally compatible with breastfeeding at low doses. [10]

Adolescents

The FDA requires a black-box warning for all antidepressants in patients under 25, citing increased risk of suicidal ideation during the first weeks of treatment. Missed doses in adolescent patients should prompt a check-in with the prescribing clinician, not just a simple catch-up. [1]

Cardiac Safety and the QTc Consideration

Trazodone has a modest effect on cardiac repolarization. At therapeutic doses, QTc prolongation is generally small (less than 10 ms), but additive risk exists with other QTc-prolonging agents (antipsychotics, macrolide antibiotics, methadone). [11]

A single missed dose does not produce cardiac risk from the absence of the drug. The concern runs in the opposite direction: if a patient accidentally doubles up to compensate for a missed dose, the spike in trazodone concentration combined with a co-prescribed QTc-prolonging drug could produce meaningful prolongation. This is the strongest clinical argument against double-dosing.

Patients with known prolonged QTc, recent myocardial infarction, or uncompensated heart failure should discuss any dosing irregularity with their prescriber rather than self-managing.

Priapism: A Rare but Serious Risk to Know

Trazodone-induced priapism occurs in an estimated 1 in 6,000 male patients. [1] The mechanism involves alpha-1 adrenergic blockade impairing detumescence. Priapism is a urologic emergency; erections lasting more than 4 hours require immediate intervention to prevent permanent erectile dysfunction.

This risk is not directly related to missed doses, but patients who double dose to compensate for a missed one are transiently exposed to higher peak plasma concentrations, which may increase alpha-1 blockade. The priapism risk is another reason the double-dose prohibition is absolute.

Practical Adherence Strategies for Trazodone Patients

The following decision framework is developed by the HealthRX medical team for use in telehealth clinical practice. It is not reproduced from any single published guideline.

The Trazodone Missed-Dose Decision Tree (HealthRX Clinical Framework)

1. What time is it relative to your scheduled dose?

   • Less than 3 hours since missed dose and more than 8 hours before needing to be alert: Take it now.
   • 3 to 6 hours since missed dose and more than 8 hours of alert-free time remaining: Take it now with food; note any dizziness.
   • More than 6 hours since missed dose or fewer than 8 hours before alertness needed: Skip entirely.

2. Are you on trazodone for sleep or for depression?

   • Sleep (50 to 100 mg): Skipping one night has no lasting consequence. Do not catch up.
   • Depression (150 to 400 mg): One missed dose is tolerable. Two or more consecutive missed doses warrant a prescriber call.

3. Are you on any interacting medications?

   • CYP3A4 inhibitors (ketoconazole, ritonavir): Extend the caution window; the drug lasts longer in your system.
   • QTc-prolonging agents: Do not double up under any circumstances.

4. Are you in a special population?

   • Age 65 or older, hepatic impairment, or pregnancy: Defer to the "skip it" option and contact your provider.

Adherence tips that actually reduce missed doses:

• Pair the dose with a fixed nightly habit (brushing teeth, charging your phone).
• Use a pill organizer with day-of-week compartments rather than the prescription bottle.
• Set a phone alarm 30 minutes before intended bedtime for bedtime dosing.
• If you travel across time zones, shift the dose time by 1 hour per day rather than jumping directly to local time.

Key Drug Interactions Affecting the Missed-Dose Window

The practical catch-up window for a missed dose expands or contracts depending on what else is in the patient's medication list.

| Interacting Drug | Effect on Trazodone | Clinical Implication | |---|---|---| | Ketoconazole (CYP3A4 inhibitor) | Raises trazodone AUC by ~52% | Effect lasts longer; catch-up window narrows | | Rifampin (CYP3A4 inducer) | Reduces plasma levels significantly | Effect may already be subtherapeutic; contact prescriber | | MAOIs (phenelzine, tranylcypromine) | Serotonin syndrome risk | Absolute contraindication; do not co-prescribe | | Warfarin | Possible increased anticoagulation | Monitor INR closely after any dose change | | Other CNS depressants (benzodiazepines, opioids) | Additive sedation | Never take a catch-up dose on the same day you have used other CNS depressants |

The FDA prescribing label specifically warns against combining trazodone with MAOIs. At least 14 days must separate an MAOI and trazodone initiation in either direction. [1]